A Phase 1/2 interventional study of MK-1045 in Acute Lymphoblastic Leukemia, sponsored by MSD R&D (China) Co., Ltd.. Recruiting at 11 sites in China. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by MSD R&D (China) Co., Ltd. (part of Merck & Co., Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.
Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 21st largest by planned enrollment of the 209 interventional ones that give a count, is one of 28 that started in 2022, is one of 33 in phase 1/2, reaches primary completion later than 105 of the 124 other live ones, and was the 126th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 475 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14–75
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14–60
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14–60
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 12–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 372 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 259 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
232 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 99 · Phase 2 89 · Phase 3 26 · Phase 4 14
First in 2008; this study’s year is marked. 28 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 203 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 45 across the 209 interventional studies, 138 across the 23 observational. Of the 40 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 232 have an industry lead sponsor. The 10 most frequent:
This study is registered under MSD R&D (China) Co., Ltd., one of the names counted as Merck & Co., Inc. Under that name alone:
MSD R&D (China) Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Merck & Co., Inc has 8 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
25 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07203352Phase 3Nanfang Hospital, Southern Medical UniversityEfficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL | 2026-12-01 |
| NCT05681260Phase 3Children's Cancer Group, ChinaCapizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) | 2026-12-31 |
| NCT07059156Phase 3Shanxi Bethune HospitalMulticenter Study of Combined Chemotherapy and Transplantation for Adult ALL | 2027-06 |
| NCT06052813Institut de Recherches Internationales Servier (I.R.I.S.)A Study of BN104 in the Treatment of Acute Leukemia | 2026-12 |
| NCT07515430Sun Yat-sen UniversityThe Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia | 2026-12-01 |
Add all 25 to your calendar (.ics) → With an account.
Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for new ways to treat people with a type of blood cancer called precursor B-cell Acute Lymphoblastic Leukemia (B-ALL) that is relapsed- the cancer has come back after treatment, or refractory - the current treatment has stopped working to slow or stop cancer growth. This study will have two parts. In the first part (dose escalation phase) the goal is to learn about the safety of a study treatment, MK-1045, and to find the best dose level of MK-1045 that is tolerated and may work to treat B-ALL. In the second part (Phase II) researchers want to learn how well MK-1045 works to treat B-ALL.
The criteria were revised on the registry on Oct 30, 2026. See what changed
The main inclusion criteria include but are not limited to:
Participants with Ph-negative B-ALL with any of the following /relapse criteria:
The main exclusion criteria include but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults in the dose escalation phase will receive a target dose level of MK-1045 from 600 μg to 120,000 μg, administered by intravenous (IV) infusion. MK-1045 will be administered once per week, in treatment cycles defined as 4 weeks of MK-1045 treatment.
Drug: MK-1045
Pediatric participants will receive a target dose level of MK-1045 from 320 μg to 60000 μg, with dosing further based upon weight. MK-1045 will be administered by IV infusion once per week, in treatment cycles defined as 4 weeks of MK-1045 treatment.
Drug: MK-1045
MK-1045 is administered by IV infusion once a week (QW), 4 weeks per treatment cycle, starting with 2 cycles of induction treatment. After a 2-week treatment-free interval, responders to induction treatment receive 3 cycles of consolidation therapy, and up to 7 cycles of maintenance treatment or until intolerable toxicity, disease progression, withdrawal of informed consent, loss to follow-up, receipt of other antitumor therapy, or death, whichever occurs first. Following each consolidation and maintenance cycle, there are treatment-free intervals ranging 2-8 weeks.
Also known as: CN201
Dose Escalation Phase: Number of Participants who Experience at Least One Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 24 months
Dose Escalation Phase: Number of Participants who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 21 months
Dose Escalation Phase: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)
A DLT is defined as any of the following toxicities and judged by the investigator to be related to the study drug: Hematologic toxic reactions: Due to the influence of the primary disease (leukemia), thrombocytopenia, leukopenia, and anemia are not considered as DLTs. Non-Hematologic toxic reactions: Grade 4 non-hematologic toxicity that does not recover to ≤ Grade 2 within 14 days of best supportive therapy. Grade 3 rash, fatigue, fever, or infection will not be classified as DLT; other Grade 3 non-hematologic toxicities that do not recover to ≤ Grade 2 within 14 days of best supportive therapy is considered DLTs. Others that are considered as DLTs: Other toxicities considered by the investigator that result in permanent drug withdrawal.
Time frame: Up to 28 days
Dose Escalation Phase: Maximum Tolerated Dose (MTD) of MK-1045
The MTD will be determined based on the incidence of DLT in each dose level. The dose level for which the DLT rate is closest to the target DLT rate (30%) will be selected as the MTD.
Time frame: Up to approximately 21 months
Phase II: Complete Remission (CR) Rate
Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. The number of participants with CR will be presented.
Time frame: Up to approximately 10 weeks
Dose Escalation Phase: Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-1045
Blood samples will be collected to determine the AUC from time 0 to the last concentration that can be accurately measured of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of MK-1045
Blood samples will be collected to determine the AUC0-inf of MK-1045.
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Area Under the Concentration-time Curve From Time 0 to 168 hours (AUC0-168)
Blood samples will be collected to determine the AUC from time to 168 hours after the start of infusion of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: AUC From Time 0 to 168 Hours at Steady State (AUC0-tau)
Blood samples will be collected to determine the AUC0 -tau
Time frame: At designated time points up to 24 weeks
Dose Escalation Phase: Maximum Serum Drug Concentration (Cmax) of MK-1045
Blood samples will be collected to determine the maximum serum drug concentration, obtained directly from the measured value of the plasma concentration-time curve
Time frame: At designated time points up to approximately 32 weeks
Dose Escalation Phase: Time to Maximum Serum Drug Concentration of MK-1045
Blood samples will be collected to determine the Tmax of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Concentration at End of Dosing Interval (Ctrough) of MK-1045
Blood samples will be collected to determine the Ctrough of MK-1045
Time frame: At designated time points up to approximately 12 months
Dose Escalation Phase: Apparent Terminal Half Life (t1/2)
Blood samples will be collected to determine the t1/2 of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Apparent Clearance (CL) of MK-1045
Blood samples will be collected to determine the CL of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Apparent Volume of Distribution (Vz) of MK-1045
Blood samples will be collected to determine the Vz of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Apparent Volume of Distribution at Theoretical Steady State (Vss) of MK-1045
Blood samples will be collected to determine the Vss of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Mean Residence Time (MRT) of MK-1045
Blood samples will be collected to determine the MRT of MK-1045
Time frame: At designated time points up to approximately 24 weeks
Dose Escalation Phase: Peripheral B Cell Depletion of MK-1045
B cell depletion will be determined at each timepoint by comparing absolute B cell numbers (as determined by flow cytometry) with those at baseline
Time frame: Baseline and at designated time points up to approximately 12 months
Dose Escalation Phase: Peripheral Circulating T Cell Activation of of MK-1045
Peripheral circulating T cell activation will be determined at each timepoint by comparing absolute T cell numbers and T cell activation markers with those at baseline
Time frame: Baseline and at designated time points up to approximately 12 months
Dose Escalation Phase: Percentage of Participants with Antidrug Antibodies (ADA) to MK-1045
Blood samples collected at designated timepoints will be used to determine the percentage of participants who develop detectable ADAs to MK-1045
Time frame: At designated time points up to approximately 12 months
Dose Escalation Phase: Rate of Complete Remission (CR) and Complete Remission with Partial Hematologic Recovery (CRh)
Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). The percentage of participants with CR or CRh will be presented.
Time frame: Up to approximately 10 weeks
Dose Escalation Phase: Rate of CR, CRh, and Complete Response with Incomplete Hematologic Recovery (CRi)
Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). CRi is defined as follows: \<5% blasts in the bone marrow, No circulating lymphoblasts or extramedullary disease, and platelets \<100×10\^9/L and neutrophils ≥1.0×109/L or platelets ≥100 ×109/L and neutrophils \<1.0×10\^9/L. The percentage of participants with CR, CRh or CRi will be presented.
Time frame: Up to approximately 10 weeks
Dose Escalation Phase: Rate of Minimum Residual Disease (MRD)-negative Complete Remission
MRD-negative is defined as less than 0.01% of leukemic cells were detected in bone marrow with a detection sensitivity no less than 10\^-4.
Time frame: Up to approximately 12 months
Dose Escalation Phase: Rate of Red Blood Cell and Platelet Transfusion Independence (TI)
TI is defined as no transfusion for a period of at least 1 week (7 days). The percentage of participants having TI will be presented.
Time frame: Up to approximately 24 months
Phase II: Number of Participants Who Experience at Least 1 AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 24 months
Phase II: Number of Participants who Discontinue Study Treatment Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Time frame: Up to approximately 24 months
Phase II: Maximum Serum Drug Concentration (Cmax) of MK-1045
Blood samples will be collected to determine the maximum serum drug concentration, obtained directly from the measured value of the plasma concentration-time curve
Time frame: At designated time points up to 4 weeks
Phase II: Concentration at End of Dosing Interval (Ctrough) of MK-1045
Blood samples will be collected to determine the Ctrough of MK-1045
Time frame: At designated time points up to 4 weeks
Phase II: Peripheral B Cell Depletion of MK-1045
B cell depletion will be determined at each timepoint by comparing absolute B cell numbers (as determined by flow cytometry) with those at baseline
Time frame: Baseline and at designated time points up to 4 weeks
Phase II: Peripheral Circulating T Cell Activation of of MK-1045
Peripheral circulating T cell activation will be determined at each timepoint by comparing absolute T cell numbers and T cell activation markers with those at baseline
Time frame: Baseline and at designated time points up to 4 weeks
Phase II: Concentration of Peripheral Cytokines
Blood samples will be collected to compare peripheral blood cytokine levels at various time points with those at baseline
Time frame: Baseline and at designated time points up to 4 weeks
Phase II: Percentage of participants with Antidrug Antibodies (ADA) to MK-1045
Blood samples collected at designated timepoints will be used to determine the percentage of participants who develop detectable ADAs to MK-1045
Time frame: At designated time points up to 4 weeks
Phase II: Rate of CR and CRh
Complete remission is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). The percentage of participants with CR or CRh will be presented.
Time frame: Up to approximately 10 weeks
Phase II: Rate of CR/CRh/CRi
CR is defined as follows: \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L. CRh is defined as meeting all of the following criteria: Satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L). CRi is defined as follows: \<5% blasts in the bone marrow, No circulating lymphoblasts or extramedullary disease, and platelets \<100×10\^9/L and neutrophils ≥1.0×109/L or platelets ≥100 ×109/L and neutrophils \<1.0×10\^9/L. The percentage of participants with CR, CRh or CRi will be presented.
Time frame: Up to approximately 10 weeks
Phase II: Rate of Minimum Residual Disease (MRD)-negative Complete Remission
MRD-negative is defined as less than 0.01% of leukemic cells were detected in bone marrow with a detection sensitivity no less than 10\^-4.
Time frame: Up to approximately 24 months
Phase II: Rate of Red Blood Cell and Platelet TI
Red Blood Cell and Platelet TI is defined as no transfusion for a period of at least 1 week (7 days). The percentage of participants having TI will be presented.
Time frame: Up to approximately 24 months
Phase II: Proportion of Participants Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
The number of participants who undergo a HSCT during study participation will be presented.
Time frame: Up to approximately 24 months
Phase II: Duration of CR
For participants who demonstrate a CR (defined as \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L) , duration of CR is defined as the time from the first documentation of a disease response of CR to the date of the first documented relapse event, or death due to any cause, whichever occurs first
Time frame: Up to approximately 24 months
Phase II: Duration of CR/CRh
Duration of CR/CRh is defined as the time from the first documentation of a disease response of CR/CRh to the date of the first documented relapse event, or death due to any cause, whichever occurs first. Only participants who demonstrate a CR (defined as \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L), or CRh \[satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L)\] will be analyzed.
Time frame: Up to approximately 24 months
Phase II: Duration of CR/CRh/CRi
Duration of CR/CRh/CRi is defined as the time from the first documentation of a disease response of CR/CRh/CRi to the date of the first documented relapse event, or death due to any cause, whichever occurs first. Only participants who demonstrate a CR (defined as \< 5% blasts in the bone marrow, no circulating lymphoblasts or extramedullary disease, and full recovery of peripheral blood counts: Platelets ≥100×10\^9/L, and absolute neutrophil count (ANC) ≥1.0×10\^9/L), or CRh \[satisfaction of all criteria for CR except partial recovery of peripheral blood counts (platelets ≥ 50 ×10\^9/L and ANC ≥ 0.5×10\^9/L)\], or CRi (\<5% blasts in the bone marrow, No circulating lymphoblasts or extramedullary disease, and platelets \<100×10\^9/L and neutrophils ≥1.0×109/L or platelets ≥100 ×109/L and neutrophils \<1.0×10\^9/L) will be analyzed.
Time frame: Up to approximately 24 months
Phase II: Relapse-Free Survival (RFS)
RFS is defined as the time from the first dose of MK-1045 to the first documented relapse, or death due to any cause (whichever occurs first). In participants who achieve CR, CRh or CRi, relapse is defined as either hematological or extramedullary relapse . Hematological relapse is defined as recurrence of blasts in the blood, or \>5% blasts in bone marrow. Extramedullary relapse is defined as recurrence of extramedullary disease after a CR.
Time frame: Up to approximately 24 months
Phase II: Overall Survival (OS)
OS is the time from date of first study treatment to the date of death due to any reason.
Time frame: Up to approximately 24 months
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Started Nov 2022 (actual). Primary completion is estimated for Dec 2028, 73 months after the start.
Of 114 phase 1/2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 119. This study's planned 73 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Anti-CD19/CD3 Bispecific Antibody MK-1045
Precursor Cell Lymphoblastic Leukemia-Lymphoma →